JPMorgan Chase & Co. Cuts Teladoc Health (NYSE:TDOC) Price Target to $7.00

Teladoc Health (NYSE:TDOC) had its price target reduced by equities researchers at JPMorgan Chase & Co. from $9.00 to $7.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a “neutral” rating on the health services provider’s stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 32.95% from the company’s current price.

Several other brokerages have also recently commented on TDOC. Bank of America raised shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 price objective for the company in a research note on Thursday, February 26th. TD Cowen lowered their target price on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Thursday, February 26th. BMO Capital Markets cut their price target on shares of Teladoc Health from $8.00 to $5.00 and set a “market perform” rating for the company in a report on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Teladoc Health in a report on Monday, December 29th. Finally, Deutsche Bank Aktiengesellschaft upgraded Teladoc Health from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research report on Tuesday. Six research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $7.72.

Teladoc Health Price Performance

TDOC traded down $0.10 during trading on Friday, reaching $5.27. 1,212,790 shares of the company were exchanged, compared to its average volume of 6,819,761. Teladoc Health has a 12-month low of $4.40 and a 12-month high of $9.77. The company’s 50-day moving average is $5.66 and its two-hundred day moving average is $7.07. The company has a quick ratio of 2.67, a current ratio of 2.77 and a debt-to-equity ratio of 0.72. The company has a market cap of $939.28 million, a price-to-earnings ratio of -4.64 and a beta of 2.13.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. Teladoc Health had a negative return on equity of 9.13% and a negative net margin of 7.92%.The business had revenue of $642.27 million during the quarter, compared to analyst estimates of $635.33 million. During the same quarter in the previous year, the firm earned ($0.28) EPS. The company’s quarterly revenue was up .3% compared to the same quarter last year. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Research analysts forecast that Teladoc Health will post -1.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Teladoc Health news, CEO Charles Divita III sold 27,731 shares of Teladoc Health stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $5.49, for a total transaction of $152,243.19. Following the completion of the sale, the chief executive officer directly owned 364,784 shares in the company, valued at $2,002,664.16. The trade was a 7.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.58% of the stock is owned by corporate insiders.

Institutional Trading of Teladoc Health

Several institutional investors and hedge funds have recently made changes to their positions in the stock. PNC Financial Services Group Inc. grew its position in Teladoc Health by 177.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after acquiring an additional 2,810 shares in the last quarter. IFP Advisors Inc raised its position in Teladoc Health by 412.1% during the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after purchasing an additional 3,210 shares in the last quarter. Aster Capital Management DIFC Ltd raised its position in Teladoc Health by 101.1% during the third quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider’s stock valued at $37,000 after purchasing an additional 2,425 shares in the last quarter. International Assets Investment Management LLC bought a new stake in Teladoc Health during the fourth quarter worth about $45,000. Finally, Bayforest Capital Ltd purchased a new position in shares of Teladoc Health in the 3rd quarter worth about $58,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Key Headlines Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Zacks Research revised a wide set of near‑ and medium‑term EPS estimates upward (notably FY2026 to -$0.99 from -$1.11 and FY2027 to -$1.02 from -$1.10), improving the company’s profitability trajectory and reducing expected losses. This helps justify recent analyst upgrade interest.
• Positive Sentiment: Deutsche Bank upgraded TDOC to a buy, signaling growing institutional conviction after Teladoc’s BetterHelp strength, earnings beat and strategic AI/international plans. Such upgrades can attract new flows and support the stock. Deutsche Bank upgrade
• Positive Sentiment: Coverage pieces highlight that analyst upgrades and an earnings surprise have put Teladoc back on investors’ radar, emphasizing BetterHelp, AI initiatives and international expansion as potential growth drivers that could re-rate the valuation if execution continues. Valuation/analysis article
• Neutral Sentiment: Recent Zacks quarter-to-quarter estimate tweaks include a very small downgrade for Q3 2027 (from -$0.25 to -$0.26) — a minor variance within a broader pattern of upward revisions; not likely to move the stock materially by itself.
• Negative Sentiment: Teladoc’s CEO, Charles Divita III, sold 27,731 shares at about $5.49. Insider sales can be perceived negatively by the market even if they are routine or for personal reasons. SEC Form 4
• Negative Sentiment: Short‑term price weakness and below‑average intraday volume raise the risk of limited buying support; the stock remains well below its 200‑day moving average, which can weigh on investor confidence.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.